newsfilter
← Latest News
PR Newswire·

Eiger BioPharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Active Dialogue with FDA on Potential Peginterferon Lambda COVID-19 EUA Application Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Planned by Year End Phase 3 Congenital Hyperinsulinism AVANT (avexitide) Program Initiated Approval of Zokinvy in E